Here’s what you should know:
1. Allergan CEO Brent Saunders is focusing on the company’s medical aesthetics, central nervous system, eye care and gastrointestinal lines.
2. The company has been losing value hand over fist since July 2017. To date, Allergan’s stock has dropped 40.93 percent.
3. Allergan’s board has considered a bevy of options like splitting the company or making acquisitions, but selling the two non-core offerings was the only unanimous decision.
4. RBC Capital Markets analyst Randall Stanicky believes the infectious disease business is worth around $1.5 billion, while the women’s health business is worth $3 billion.
More articles on supply chain:
Senator’s proposal to lower healthcare costs touts ASC, physician-owned hospital use: 5 things to know
22 statistics on ASC case volume
31 updates for ASC leaders to know — May 2018
